CY1120341T1 - Ενωση βενζοθειοφαινιου - Google Patents
Ενωση βενζοθειοφαινιουInfo
- Publication number
- CY1120341T1 CY1120341T1 CY20181100635T CY181100635T CY1120341T1 CY 1120341 T1 CY1120341 T1 CY 1120341T1 CY 20181100635 T CY20181100635 T CY 20181100635T CY 181100635 T CY181100635 T CY 181100635T CY 1120341 T1 CY1120341 T1 CY 1120341T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pain
- osteoarthritic
- channel
- inflammatory
- sulfate compound
- Prior art date
Links
- -1 Benzene Sulfate Compound Chemical class 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 abstract 4
- 230000003349 osteoarthritic effect Effects 0.000 abstract 4
- 206010065390 Inflammatory pain Diseases 0.000 abstract 3
- 208000001640 Fibromyalgia Diseases 0.000 abstract 2
- 239000012190 activator Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000009935 visceral pain Diseases 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000012790 confirmation Methods 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N thianaphthalene Natural products C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Οι εφευρέτες τελειοποίησαν την παρούσα εφεύρεση ως αποτέλεσμα κάποιας μελέτης για τους ενεργοποιητές του διαύλου ΙΚ1 και μιας επιβεβαίωσης ότι κάποια ένωση βενζοθειοφαινίου εμφανίζει δραστικότητα έναντι του σπλαγχνικού πόνου, του φλεγμονώδους πόνου, του οστεοαρθριτικού πόνου, του νευροπαθητικού πόνου ή της ινομυαλγίας. Η παραπάνω ένωση, η οποία αντιπροσωπεύεται από τον χημικό τύπο (I), έχει δράση ενεργοποίησης του διαύλου ΙΚ1, και είναι πιθανόν να χρησιμοποιηθεί ως φάρμακο στην πρόληψη ή τη θεραπεία του σπλαγχνικού πόνου, του φλεγμονώδους πόνου, του οστεοαρθριτικού πόνου, του νευροπαθητικού πόνου, της ινομυαλγίας και τα τοιαύτα. Ο ενεργοποιητής του διαύλου ΙΚ1 μπορεί να χρησιμοποιηθεί ως φάρμακο στην πρόληψη ή τη θεραπεία του φλεγμονώδους πόνου, του οστεοαρθριτικού πόνου, του νευροπαθητικού πόνου ή της ινομυαλγίας.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013119416 | 2013-06-06 | ||
| PCT/JP2014/065141 WO2014196644A1 (ja) | 2013-06-06 | 2014-06-06 | ベンゾチオフェン化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120341T1 true CY1120341T1 (el) | 2019-07-10 |
Family
ID=52005968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100635T CY1120341T1 (el) | 2013-06-06 | 2018-06-19 | Ενωση βενζοθειοφαινιου |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8981119B2 (el) |
| EP (1) | EP3006443B1 (el) |
| JP (1) | JP6314978B2 (el) |
| KR (1) | KR102253721B1 (el) |
| CN (1) | CN105263926B (el) |
| AR (1) | AR096544A1 (el) |
| AU (1) | AU2014275768B2 (el) |
| BR (1) | BR112015030533B1 (el) |
| CA (1) | CA2914606C (el) |
| CY (1) | CY1120341T1 (el) |
| DK (1) | DK3006443T3 (el) |
| ES (1) | ES2671818T3 (el) |
| HK (1) | HK1215570A1 (el) |
| HR (1) | HRP20180722T1 (el) |
| HU (1) | HUE038920T2 (el) |
| IL (1) | IL242800B (el) |
| LT (1) | LT3006443T (el) |
| MX (1) | MX2015016743A (el) |
| NO (1) | NO3006443T3 (el) |
| PH (1) | PH12015502637A1 (el) |
| PL (1) | PL3006443T3 (el) |
| PT (1) | PT3006443T (el) |
| RS (1) | RS57250B1 (el) |
| RU (1) | RU2667507C2 (el) |
| SG (1) | SG11201509989VA (el) |
| SI (1) | SI3006443T1 (el) |
| TR (1) | TR201808724T4 (el) |
| TW (1) | TWI624466B (el) |
| UA (1) | UA117484C2 (el) |
| WO (1) | WO2014196644A1 (el) |
| ZA (1) | ZA201508866B (el) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022541634A (ja) | 2019-07-23 | 2022-09-26 | アステラス ファーマ グローバル ディベロップメント，インコーポレーテッド． | 疼痛に関連する睡眠障害を治療する方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614639A (en) * | 1995-03-31 | 1997-03-25 | Eli Lilly And Company | Process for preparing 2-substituted benzo[b]thiophene compounds and intermediates thereof |
| EP1358150A1 (en) * | 2001-02-06 | 2003-11-05 | Glaxo Group Limited | Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity |
| WO2003005025A1 (en) * | 2001-07-03 | 2003-01-16 | Biovitrum Ab | Methods for identifying compounds modulating the activity of ppar-gamma |
| CN1798738A (zh) | 2003-04-03 | 2006-07-05 | 麦克公司 | 作为钠通道阻滞剂的联芳基取代吡唑 |
| RU2006104621A (ru) | 2003-07-15 | 2006-08-27 | Смитклайн Бичам Корпорейшн (US) | Новые соединения |
| WO2008054435A2 (en) * | 2006-01-09 | 2008-05-08 | The Regents Of The University Of California | Use of sk channel activators to prevent relapse/reinstatement of drugs of abuse |
| US8022209B2 (en) | 2007-09-12 | 2011-09-20 | Janssen Pharmaceutica Nv | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor |
| AU2009311585A1 (en) * | 2008-11-10 | 2010-05-14 | Boehringer Ingelheim International Gmbh | Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels |
| AR090037A1 (es) | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
-
2014
- 2014-06-06 EP EP14807340.6A patent/EP3006443B1/en active Active
- 2014-06-06 TW TW103119735A patent/TWI624466B/zh active
- 2014-06-06 NO NO14807340A patent/NO3006443T3/no unknown
- 2014-06-06 SG SG11201509989VA patent/SG11201509989VA/en unknown
- 2014-06-06 DK DK14807340.6T patent/DK3006443T3/en active
- 2014-06-06 AU AU2014275768A patent/AU2014275768B2/en active Active
- 2014-06-06 TR TR2018/08724T patent/TR201808724T4/tr unknown
- 2014-06-06 SI SI201430718T patent/SI3006443T1/en unknown
- 2014-06-06 RU RU2015152150A patent/RU2667507C2/ru active
- 2014-06-06 MX MX2015016743A patent/MX2015016743A/es active IP Right Grant
- 2014-06-06 ES ES14807340.6T patent/ES2671818T3/es active Active
- 2014-06-06 CA CA2914606A patent/CA2914606C/en active Active
- 2014-06-06 UA UAA201512058A patent/UA117484C2/uk unknown
- 2014-06-06 JP JP2015521510A patent/JP6314978B2/ja active Active
- 2014-06-06 US US14/298,208 patent/US8981119B2/en active Active
- 2014-06-06 KR KR1020157036601A patent/KR102253721B1/ko active IP Right Grant
- 2014-06-06 CN CN201480031630.3A patent/CN105263926B/zh active Active
- 2014-06-06 PT PT148073406T patent/PT3006443T/pt unknown
- 2014-06-06 LT LTEP14807340.6T patent/LT3006443T/lt unknown
- 2014-06-06 BR BR112015030533-4A patent/BR112015030533B1/pt active IP Right Grant
- 2014-06-06 WO PCT/JP2014/065141 patent/WO2014196644A1/ja active Application Filing
- 2014-06-06 HU HUE14807340A patent/HUE038920T2/hu unknown
- 2014-06-06 RS RS20180626A patent/RS57250B1/sr unknown
- 2014-06-06 PL PL14807340T patent/PL3006443T3/pl unknown
- 2014-06-06 AR ARP140102207A patent/AR096544A1/es active IP Right Grant
-
2015
- 2015-01-23 US US14/604,404 patent/US9399038B2/en not_active Expired - Fee Related
- 2015-11-26 PH PH12015502637A patent/PH12015502637A1/en unknown
- 2015-11-26 IL IL242800A patent/IL242800B/en active IP Right Grant
- 2015-12-03 ZA ZA2015/08866A patent/ZA201508866B/en unknown
-
2016
- 2016-03-24 HK HK16103490.1A patent/HK1215570A1/zh unknown
-
2018
- 2018-05-10 HR HRP20180722TT patent/HRP20180722T1/hr unknown
- 2018-06-19 CY CY20181100635T patent/CY1120341T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123164T1 (el) | Διεργασια για τη συνθεση ενος αναστολεα ινδολαμινης 2,3-διοξυγενασης | |
| CY1122671T1 (el) | Θεραπευτικως δραστικες ενωσεις και οι μεθοδοι χρησεις αυτων | |
| CY1120969T1 (el) | Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης | |
| BR112016006209A2 (pt) | composição de polímero termoplástico | |
| CU20160120A7 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| CY1120173T1 (el) | Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| CL2015002194A1 (es) | Inhbidores de erk y sus usos | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| CR20160456A (es) | Compuestos de heteroarilo o arilo bibíclicos fusionados | |
| BR112015019432A2 (pt) | Compostos de tubulisina, métodos de produção e uso | |
| EA201591340A1 (ru) | Модулятор андрогенного рецептора и его применения | |
| BR112015030203A2 (pt) | moléculas pequenas inibidores da fibrose | |
| CY1122805T1 (el) | Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων | |
| BR112017000301A2 (pt) | tratamento de leucemia com inibidores de histona desacetilase | |
| CL2016000436A1 (es) | Método para el tratamiento de la enfermedad fibrótica | |
| CY1123842T1 (el) | Ετεροαρυλικες ενωσεις για τη θεραπευτικη αντιμετωπιση οφθαλμικων νοσων | |
| CY1122971T1 (el) | Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων | |
| CO2017000552A2 (es) | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70 | |
| EA201792096A3 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
| DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| EA201690227A1 (ru) | Азаиндольные соединения, их получение и способы их применения | |
| CY1121279T1 (el) | Ετεροκυκλικη ενωση |